Scabies Lesion Lysate (human)

For diagnostic purposes, the dosage of Scabies Lesion Lysate (human) is not measured in milligrams but in volume and standardized units of potency (such as Protein Nitrogen Units or PNU).

• Intradermal Testing: The standard adult dose is typically 0.02 mL to 0.05 mL of a diluted extract. This is injected using a 26- or 27-gauge needle to create a small 'bleb' or blister on the volar surface of the forearm.
• Prick/Scratch Testing: One drop of the concentrated lysate is applied to the skin, which is then lightly pricked. This method uses a much smaller amount of the substance than intradermal testing.

Scabies Lesion Lysate (human) has not been extensively studied in pediatric populations under the age of 6. For children older than 6, healthcare providers may use a more diluted concentration to minimize the risk of a systemic reaction. The volume remains similar (0.02 mL), but the antigenic load is often reduced.

> Warning: Pediatric testing must be performed with extreme caution, as children may be more susceptible to rapid-onset systemic reactions.

Renal Impairment

No dosage adjustments are typically required for patients with renal impairment, as the systemic absorption of the lysate is negligible. However, patients with end-stage renal disease (ESRD) may have altered skin reactivity (uremic pruritus), which can make the interpretation of results difficult.

Hepatic Impairment

No adjustments are necessary for hepatic impairment. The metabolism of the lysate occurs locally at the site of injection and does not rely on liver function.

Elderly Patients

In elderly patients, skin reactivity may be diminished due to age-related changes in the immune system (immunosenescence). Healthcare providers may need to adjust the concentration or carefully select the site of testing to ensure a valid response.

This product is never self-administered. It must be administered by a healthcare professional in a clinical setting.

• Preparation: The skin site (usually the forearm) is cleaned with alcohol and allowed to dry.
• Administration: The provider will perform the injection or prick. You will be asked to remain in the office for at least 30 minutes following the procedure.
• Reading: An initial reading occurs at 15-20 minutes. You may be asked to return 48 to 72 hours later for a delayed-response reading.
• Storage: Vials should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze.

Since this is a diagnostic test and not a daily medication, a 'missed dose' refers to a missed appointment. If you miss your testing appointment, contact your allergist to reschedule. The timing of the 'reading' of the skin test is critical; if you cannot return for the 48-hour check, the test may need to be repeated.

An 'overdose' in the context of an allergenic extract refers to the administration of too high a concentration or too large a volume, which can trigger a systemic allergic reaction or anaphylaxis.

• Signs of Overdose/Systemic Reaction: Hives, swelling of the throat, difficulty breathing, rapid heart rate, or a sudden drop in blood pressure.
• Emergency Measures: If a systemic reaction occurs, the provider will immediately administer epinephrine (Adrenalin) and may provide antihistamines or corticosteroids. Emergency medical services (EMS) will be summoned if the reaction is severe.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to apply this substance yourself without medical guidance.

Most patients receiving Scabies Lesion Lysate (human) will experience local reactions at the site of administration. These are often expected as part of the diagnostic process.

• Local Erythema (Redness): A red patch around the injection site is very common. It usually appears within minutes and may last for several hours.
• Pruritus (Itching): Significant itching at the site is common, especially if the test is positive. This indicates the immune system is responding to the antigens.
• Wheal Formation: A raised, white or pale bump (similar to a mosquito bite) is the standard positive result for an immediate hypersensitivity test.
• Tenderness: The site may feel slightly sore or tender to the touch for 24 to 48 hours.

• Induration (Hardening): The area around the injection may become firm or hard. This is more common in delayed-type hypersensitivity reactions.
• Local Swelling (Edema): Swelling that extends beyond the immediate injection site, sometimes involving a large portion of the forearm.
• Persistent Discoloration: A small area of hyperpigmentation (darkening of the skin) or bruising may remain for several days after the test.

• Lymphangitis: Inflammation of the lymph vessels, appearing as red streaks extending from the injection site toward the elbow or armpit.
• Small Vesicles: Tiny blisters may form at the site of the skin test if the reaction is particularly intense.
• Syncope (Fainting): Some patients may experience a vasovagal response (fainting) due to the needle stick rather than the lysate itself.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of these systemic symptoms after administration.

• Anaphylaxis: A life-threatening allergic reaction characterized by a sudden drop in blood pressure, narrowing of the airways, and a rapid, weak pulse.
• Angioedema: Deep swelling of the tissues, most dangerously around the lips, tongue, or throat, which can obstruct breathing.
• Generalized Urticaria: Hives that spread across the entire body, not just at the injection site.
• Wheezing or Bronchospasm: Difficulty breathing or a whistling sound when breathing, indicating airway constriction.
• Hypotension: Feeling severely dizzy or lightheaded, which may indicate a dangerous drop in blood pressure.

Because Scabies Lesion Lysate (human) is used for short-term diagnostic purposes, long-term side effects are extremely rare. There is a theoretical risk of 'sensitization,' where the test itself causes the patient to become allergic to scabies proteins when they were not before, though this is unlikely with standardized, low-dose extracts. In rare cases, a 'granuloma' (a small knot of immune cells) may form at the injection site and persist for several weeks.

No FDA black box warnings currently exist for Scabies Lesion Lysate (human). However, like all allergenic extracts, it carries a general warning regarding the risk of severe systemic reactions, including anaphylaxis. It must only be administered by clinicians prepared to manage such emergencies.

Report any unusual symptoms, especially those occurring hours after leaving the clinic, to your healthcare provider.

Scabies Lesion Lysate (human) is a potent biological agent. Its use is restricted to diagnostic environments where the patient can be monitored for at least 30 minutes post-injection. Patients with a history of severe asthma or those currently experiencing an unstable respiratory condition are at a higher risk for complications during skin testing.

No FDA black box warnings for Scabies Lesion Lysate (human) are currently issued. However, the FDA requires all allergenic extracts to be labeled with warnings regarding the potential for severe systemic allergic reactions. Clinicians are advised that the benefit of diagnosis must outweigh the risk of provocation in highly sensitive individuals.

• Anaphylaxis Risk: The most significant risk is a systemic allergic reaction. This is more likely in patients with high levels of pre-existing IgE antibodies to scabies or related mites (such as dust mites).
• Asthma Exacerbation: Patients with poorly controlled asthma may experience a flare-up of their respiratory symptoms if a systemic reaction occurs. Asthma should be stable before testing begins.
• Dermatological Conditions: Testing should not be performed on skin areas affected by active eczema, psoriasis, or severe dermatitis, as this can lead to 'false positive' results (Angry Back Syndrome) or worsen the underlying skin condition.
• Infection Risk: As with any intradermal procedure, there is a minor risk of introducing bacteria into the skin, leading to localized infection (cellulitis).

Patients do not typically require long-term lab monitoring (like blood counts or liver tests) for a single diagnostic use. However, the following 'immediate' monitoring is required:

• Observation Period: A minimum of 30 minutes of direct observation by medical staff after the injection.
• Vital Signs: Baseline blood pressure and heart rate may be taken, especially in patients with cardiovascular disease.
• Peak Flow: In asthmatic patients, a peak flow meter may be used to ensure no airway obstruction is occurring.

Scabies Lesion Lysate (human) does not usually affect the ability to drive. However, if you experience a vasovagal response (dizziness) or a systemic reaction, you should not drive until you are fully recovered and cleared by a medical professional.

There is no direct interaction between alcohol and the lysate. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically increase the rate of absorption or worsen the redness at the test site. It is best to avoid alcohol for 24 hours before and after the test.

As this is a one-time or two-time diagnostic procedure, 'discontinuation' is not applicable in the same way as chronic medication. However, if a patient reacts poorly to the initial prick test, the healthcare provider will 'discontinue' the plan to move forward with the more potent intradermal test.

> Important: Discuss all your medical conditions, especially any history of severe allergies or asthma, with your healthcare provider before starting Scabies Lesion Lysate (human).

There are no drugs that are strictly 'contraindicated' in the sense of causing a fatal chemical reaction, but certain drugs must be stopped because they make the test useless or dangerous:

• Beta-Blockers (e.g., Propranolol, Atenolol): These drugs can make a systemic allergic reaction much more difficult to treat. They block the effects of epinephrine, which is the primary treatment for anaphylaxis. Testing should be avoided if the patient cannot safely pause their beta-blocker.
• ACE Inhibitors (e.g., Lisinopril): Similar to beta-blockers, these may increase the severity of an allergic reaction and complicate treatment.

• Systemic Corticosteroids (e.g., Prednisone): High doses of steroids can suppress the immune response, leading to a 'false negative' result. Patients typically need to be off oral steroids for at least 1–2 weeks before testing.
• Immunosuppressants (e.g., Methotrexate, Cyclosporine): These medications dampen the T-cell and B-cell responses, which can significantly interfere with both immediate and delayed-type hypersensitivity readings.

• Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine): These are the most common interactors. They block the H1 receptors, preventing the 'wheal and flare' response. Most antihistamines must be stopped 3 to 7 days before testing.
• Tricyclic Antidepressants (e.g., Amitriptyline): These drugs have potent antihistamine properties and can suppress skin test reactivity for several weeks.
• H2 Blockers (e.g., Famotidine): While less potent than H1 blockers, they can still diminish the skin's response to the lysate.

There are no known direct food interactions with Scabies Lesion Lysate (human). However, patients should avoid consuming foods they are known to be allergic to on the day of the test, as this could 'prime' the immune system and increase the risk of a systemic reaction to the lysate.

• St. John's Wort: May theoretically affect skin sensitivity, though data is limited.
• High-dose Vitamin C: Some studies suggest Vitamin C has mild antihistamine effects, which could slightly dampen the test result.
• Licorice Root: May have corticosteroid-like effects that could suppress inflammation at the test site.

Scabies Lesion Lysate (human) does not typically interfere with standard blood or urine laboratory tests. However, it will interfere with other skin tests (like a TB skin test) if performed on the same arm at the same time, as the local inflammatory environment can cross-react.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'allergy pills' or 'heart medications.'

Scabies Lesion Lysate (human) must NEVER be used in the following circumstances:

• History of Anaphylaxis to Scabies Extracts: If a patient has previously had a life-threatening reaction to this or similar mite-derived extracts, the risk of re-exposure is too high.
• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) of less than 70% of predicted are at extreme risk if a systemic reaction occurs.
• Acute Systemic Illness: Testing should not be performed if the patient has a fever or an active infection, as the immune system is already 'overactive,' which can lead to unpredictable results.
• Active Scabies Infestation (Severe/Crusted): Testing a patient with an active, massive infestation (Crusted or Norwegian Scabies) is unnecessary and may trigger a massive systemic inflammatory response.

Conditions requiring careful risk-benefit analysis include:

• Pregnancy: While not strictly prohibited, elective diagnostic skin testing is usually postponed until after delivery to avoid the risk of anaphylaxis-induced fetal distress.
• Dermatographism: A condition where the skin 'overreacts' to any touch or pressure. This makes the lysate test impossible to read, as the needle stick itself will cause a wheal.
• Beta-Blocker Therapy: If the patient cannot stop their beta-blocker due to a high risk of heart attack or stroke, the skin test is usually avoided.

Patients who are highly allergic to House Dust Mites (Dermatophagoides farinae or Dermatophagoides pteronyssinus) may show a 'false positive' or cross-reactive response to Scabies Lesion Lysate (human) due to the similarity in protein structures between different mite species.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing or administering Scabies Lesion Lysate (human).

Scabies Lesion Lysate (human) is generally classified in a category similar to FDA Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not the lysate itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to maternal hypotension, which significantly reduces uterine blood flow and can cause fetal hypoxia (lack of oxygen). Therefore, diagnostic skin testing is typically deferred until the postpartum period unless the diagnosis is critical for immediate management.

It is not known whether the antigens in the lysate are excreted in human milk. However, because the dose used in skin testing is extremely small and administered locally, it is highly unlikely that any significant amount would reach the infant through breastfeeding. The risk-benefit ratio usually favors the mother if the test is necessary, but a 24-hour 'pump and discard' period can be considered if there are concerns.

Safety and effectiveness in children under the age of 6 have not been established. In older children, the test is generally safe but must be performed with smaller volumes. Children are often more reactive than adults, and the emotional stress of the needle stick can trigger vasovagal episodes. Standardized extracts are preferred to minimize the risk of over-sensitization.

Clinical studies of allergenic extracts have shown that patients over 65 may have reduced skin reactivity. This can lead to false-negative results. Additionally, elderly patients are more likely to be taking medications like beta-blockers or ACE inhibitors for cardiovascular disease, which increases the risk profile of the procedure. Providers should assess the patient's 'skin turgor' and overall immune status before testing.

Patients with chronic kidney disease (CKD) may have altered immune responses. While no dose adjustment is needed, the provider should be aware that uremia (buildup of toxins in the blood) can suppress the 'wheal and flare' response, potentially leading to an underestimation of the patient's sensitivity.

There are no specific precautions for hepatic impairment. Since the lysate is not processed by the liver's metabolic pathways, the presence of liver disease does not alter the pharmacokinetics of the diagnostic test.

> Important: Special populations require individualized medical assessment to ensure the diagnostic procedure is both safe and effective.

Scabies Lesion Lysate (human) functions as an exogenous (external) antigenic challenge. The lysate contains a complex mixture of proteins, including mite digestive enzymes, structural proteins (tropomyosin), and human cellular debris from the lesion site.

1. 1Immediate Phase (Type I Hypersensitivity): Upon injection, these antigens cross-link specific IgE antibodies bound to the surface of mast cells in the dermis. This cross-linking triggers degranulation, releasing histamine and other mediators. Histamine acts on H1 receptors on local blood vessels, causing vasodilation (redness) and increased capillary permeability (swelling/wheal).
2. 2Delayed Phase (Type IV Hypersensitivity): Antigens are taken up by dendritic cells and presented to memory T-cells. If the patient has cellular immunity to scabies, these T-cells release cytokines (like IFN-gamma and IL-2), which recruit macrophages and cause a firm, inflammatory papule over 48-72 hours.

• Dose-Response: There is a clear dose-response relationship; higher concentrations of the lysate produce larger wheal diameters in sensitized individuals.
• Time to Onset: Immediate reactions occur within 5–10 minutes and peak at 15–20 minutes. Delayed reactions begin after 6–12 hours and peak at 48–72 hours.
• Duration of Effect: The immediate wheal usually resolves within 2–4 hours. The delayed reaction can persist for several days.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local administration) |

| Protein Binding | Local tissue binding is high |

| Half-life | ~2-6 hours (local degradation) |

| Tmax | 15-20 minutes (for wheal) |

| Metabolism | Local proteolytic cleavage |

| Excretion | Lymphatic clearance |

• Composition: A sterile aqueous lysate of human skin tissue containing Sarcoptes scabiei antigens.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa (complex protein mixture).
• Solubility: Highly soluble in buffered saline solutions.
• Standardization: Potency is typically measured in Protein Nitrogen Units (PNU) or Bioequivalent Allergy Units (BAU).

Scabies Lesion Lysate (human) is classified as a Standardized Chemical Allergen. It is part of a broader group of allergenic extracts that includes pollen, mold, and insect venom extracts used in diagnostic allergy and immunology.